These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11552628)

  • 41. A case of pervasive developmental disorder complicated by social anxiety disorder responding well to fluvoxamine therapy.
    Yano H; Matsumoto H
    Tokai J Exp Clin Med; 2011 Jul; 36(2):44-6. PubMed ID: 21769772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experience of the use of velaxin (venlafaxine) in anxious depression.
    Il'ina NA
    Neurosci Behav Physiol; 2009 Mar; 39(3):305-9. PubMed ID: 19234798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?
    Matsunaga H; Kiriike N; Matsui T; Iwasaki Y; Stein DJ
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):231-7. PubMed ID: 11602029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are SSRIs really more effective for anxious depression?
    Panzer MJ
    Ann Clin Psychiatry; 2005; 17(1):23-9. PubMed ID: 15941028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy.
    Stahl SM
    J Clin Psychiatry; 1999 Apr; 60(4):213-4. PubMed ID: 10221279
    [No Abstract]   [Full Text] [Related]  

  • 49. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding.
    Gentile S
    Arch Womens Ment Health; 2006 May; 9(3):158-9. PubMed ID: 16683078
    [No Abstract]   [Full Text] [Related]  

  • 50. [The depressive patient before depression].
    Akiskal HS
    Encephale; 1992 Sep; 18 Spec No 4():485-9. PubMed ID: 1308843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity.
    Cusin C; Serretti A; Zanardi R; Lattuada E; Rossini D; Lilli R; Lorenzi C; Smeraldi E
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):27-35. PubMed ID: 12057029
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective serotonin reuptake inhibitors in mixed anxiety-depression.
    Berk M
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S41-5. PubMed ID: 11110018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depression with anxiety and atypical depression.
    Liebowitz MR
    J Clin Psychiatry; 1993 Feb; 54 Suppl():10-4; discussion 15. PubMed ID: 8444829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Substance-P antagonists: a new treatment for depression?
    Nutt D
    Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
    [No Abstract]   [Full Text] [Related]  

  • 57. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extended-release fluvoxamine (Luvox CR).
    Med Lett Drugs Ther; 2008 Jun; 50(1289):50-1. PubMed ID: 18583947
    [No Abstract]   [Full Text] [Related]  

  • 60. Pediatric generalized anxiety disorder: predictors of outcome after selective serotonin reuptake inhibitor monotherapy.
    Masi G; Mucci M; Pfanner C; Berloffa S; Liboni F; Perugi G
    J Clin Psychopharmacol; 2013 Aug; 33(4):577-9. PubMed ID: 23775050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.